What does this score mean?
The Confidence Index is not a treatment success rate; it is an editorial methodology score indicating to what extent the scientific finding evaluated on this page can be trusted. Study design, risk of bias, sample size, precision, direct applicability, reproducibility, transparency, and clinical relevance are evaluated together.
What did the study investigate?
It evaluated the safety and functional outcomes of adding iPSC-derived cardiomyocytes to CABG in advanced ischemic heart failure.
How was it conducted?
20 patients were randomized; 10 patients received iPSC-derived cardiomyocytes directly into the myocardium along with CABG, and 10 patients received CABG alone, with 12 months of follow-up.
What was found?
Greater improvement was observed in certain walking, perfusion, and regional wall motion measurements; however, no significant difference could be demonstrated in EF, ventricular volume, NYHA class, and quality of life. An arrhythmia signal drew attention.
Limitations of the study
The sample size is very small; it is insufficient for rare safety events and long-term efficacy. The presence of concurrent CABG in all patients makes it difficult to interpret the cell effect.
What does it mean clinically?
It is an important early clinical step in terms of cardiac regeneration, but it is not evidence at a level to support routine application.
What do we not know yet?
How to reduce arrhythmia risk, long-term cell persistence, the effect on mortality/hospitalization, and clear clinical benefit in larger groups remain unknown.
Source
The full citations and links to the sources are preserved in the detailed evaluation section of this page.
Written and medically reviewed by: Dr. Kerem Çağlayan · Information about cell therapies · All Scientific Research
Detailed evaluation
Research evaluation · September 5, 2026
The early-stage randomized HEAL-CHF study, published in Nature Medicine on August 19, 2026, tested human iPSC-derived cardiomyocytes in advanced ischemic heart failure. Although the study represents an important clinical step for cardiac regeneration, it does not yet support routine treatment.
How was the study conducted?
All 20 patients with advanced heart failure underwent coronary artery bypass surgery. Ten patients received iPSC-derived cardiomyocytes alongside CABG, and ten patients received CABG alone. The cells were injected directly into the heart muscle, not via intravenous infusion. Therefore, the study is not identical to applications marketed as “stem cell IVs.”
What did the results show?
At 12-month follow-up, greater improvements were reported in the cell-treated group regarding 6-minute walk distance, global myocardial perfusion, and regional heart wall thickening. In contrast, no significant differences were demonstrated between the groups in ejection fraction, left ventricular volumes, scar size, NYHA class, and quality of life.
Prominent safety signal
In the study, no tumor formation was reported within 12 months, and no sustained ventricular tachycardia was observed during the defined 1–6 month period. However, accelerated idioventricular rhythm developed in all 10 patients receiving cell therapy. In two patients, clinically significant ventricular tachycardia exceeding 140 beats/min was observed and resolved after cardioversion. Arrhythmia risk is the primary issue that future studies must address.
What is an iPSC?
An induced pluripotent stem cell is an adult cell that has been reprogrammed in the laboratory to acquire the ability to differentiate into different cell types. By generating cardiomyocytes from these cells, the aim is to provide functional cells to replace contractile tissue lost after a heart attack.
Why is it important?
Modern heart failure treatments can reduce mortality and slow remodeling; however, they cannot routinely regenerate lost heart muscle. The iPSC-cardiomyocyte approach aims to remuscularize the damaged heart rather than merely supporting it. Nevertheless, the 20-person study cannot provide definitive conclusions regarding rare side effects, death, and long-term efficacy.
Frequently asked questions
Is this a classic stem cell therapy?
No. The product consists of cardiomyocytes differentiated from iPSCs in the laboratory.
Is it currently applicable?
As a routine clinical treatment, no; larger and longer-term randomized trials are needed.
Source
Zhang H, Menasche P, Fan J et al. Intramyocardial injection of allogeneic human induced pluripotent stem cell-derived cardiomyocytes in advanced ischemic heart failure: an early-stage randomized trial. Nature Medicine. August 19, 2026. DOI.
